Everolimus in combination with mycophenolate mofetil aspre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates

7Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Abstract

The mammalian target of rapamycin inhibitor everolimus (RAD001) is a successfully used immunosuppressant in solid-organ transplantation. Several studies have already used RAD001 in combination with calcineurin inhibitors after hematopoietic stem cell transplantation (HSCT). We investigated calcineurin inhibitor-free pre- and post-transplantation immunosuppression of RAD001 combined with mycophenolate mofetil (MMF) in a nonmyeloablative HSCT setting. After nonmyeloablative conditioning with 2Gy total body irradiation, 8 dogs received HSCT from dog leukocyte antigen-identical siblings. Immunosuppressives were given at doses of 1.5mg RAD001 twice daily from day-1 to+49, then tapered until day+56, and 20mg/kg MMF from day 0 to+28, then tapered until day+42. An historical cyclosporin A (CsA)/MMF regimen was used in the control group. All dogs engrafted. Median platelet nadir amounted in all dogs to 0×109/L (median, day+10; duration <50×109/L, 22days) and median leukocyte nadir was 1.0×109/L (range, .1 to 2.5×109/L; median, day+13). Eventually, 5 of 8 (63%) animals rejected their grafts. Two dogs died of infections on day+19 and+25. Pharmacokinetics of RAD001 and MMF showed median trough levels of 19.1 (range, 10.5 to 43.2) μg/L and .3 (1 to 1.3) mg/L, respectively. The median area under the curve was 325 (range, 178 to 593) μg/L×hour for RAD001 and 29.6 (range, 7.9 to 40.5) ng/L×hour for MMF. All dogs developed clinically mucosal viral infections during the clinical course. Compared with the control group, the level of toxicities for RAD001/MMF increased in all qualities. Combined immunosuppression of RAD001 and MMF after nonmyeloablative HSCT is associated with significant toxicities, including a prolonged platelet recovery time as well as increased infections compared to the CsA/MMF regimen. © 2014 American Society for Blood and Marrow Transplantation.

Cite

CITATION STYLE

APA

Machka, C., Lange, S., Werner, J., Wacke, R., Killian, D., Knueppel, A., … Junghanss, C. (2014). Everolimus in combination with mycophenolate mofetil aspre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates. Biology of Blood and Marrow Transplantation, 20(9), 1301–1306. https://doi.org/10.1016/j.bbmt.2014.06.004

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free